Skip to Content
Merck
All Photos(1)

Documents

SML0491

Sigma-Aldrich

Ritonavir

≥98% (HPLC)

Synonym(s):

A-84538, ABT-538, Abbott 84538

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C37H48N6O5S2
CAS Number:
155213-67-5
Molecular Weight:
720.94
MDL number:
MFCD00927142
UNSPSC Code:
12352200
PubChem Substance ID:
329825441
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL (clear solution, warmed)

storage temp.

room temp

SMILES string

O=C(OCC1=CN=CS1)N[C@H]([C@@H](O)C[C@@H](NC([C@@H](NC(N(CC2=CSC(C(C)C)=N2)C)=O)C(C)C)=O)CC3=CC=CC=C3)CC4=CC=CC=C4

InChI

1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

InChI key

NCDNCNXCDXHOMX-XGKFQTDJSA-N

Application

Ritonavir has been used:
  • as a human immunodeficiency virus (HIV) protease inhibitor to study its effects on placental endocrine function
  • as an HIV protease inhibitor to study its effects on reduction of tetrazolium dye in human embryonic kidney cells
  • as an organic anion transporting polypeptide (OATP) inhibitor to study its effect on hepatic uptake of bergapten and imperatorin

Biochem/physiol Actions

Ritonavir is an HIV protease inhibitor now used frequently as a booster of other protease inhbitors. Ritonavir inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that normally metabolizes protease inhibitors. It has also been investigated as a possible anti-cancer agent.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302 + H312 + H332

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

José R Santos et al.
The Journal of antimicrobial chemotherapy, 70(4), 1124-1129 (2014-12-20)
Data on the efficacy of simplifying therapy using darunavir/ritonavir and lopinavir/ritonavir monotherapy in clinical practice remain limited. A retrospective single-centre study including patients initiating darunavir/ritonavir or lopinavir/ritonavir monotherapy with a plasma HIV-1 viral load (pVL) <50 copies/mL and at least
Lin Chen et al.
Journal of ethnopharmacology, 212, 74-85 (2017-10-23)
Radix Angelica dahuricae (RAD), the roots of Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav, is a well-known traditional Chinese medicine (TCM) and has been used for centuries to treat headaches, toothaches, nose congestion, abscesses, furunculoses, and acne.
Laura Ciaffi et al.
AIDS (London, England), 29(12), 1473-1481 (2015-08-06)
WHO recommends ritonavir-boosted protease inhibitor with two nucleoside reverse transcriptase inhibitors in HIV-infected patients failing non-nucleoside reverse transcriptase inhibitor-based first-line treatment. Here, we aimed to provide more evidence for the choice of nucleoside reverse transcriptase inhibitor and boosted protease inhibitor.
Mary S Ngoma et al.
Journal of the International AIDS Society, 18, 19352-19352 (2015-07-04)
To prevent mother-to-child transmission (MTCT) of HIV in developing countries, new World Health Organization (WHO) guidelines recommend maternal combination antiretroviral therapy (cART) during pregnancy, throughout breastfeeding for 1 year and then cessation of breastfeeding (COB). The efficacy of this approach
Maria Casadellà et al.
AIDS (London, England), 29(12), 1493-1504 (2015-08-06)
This article aims to investigate if the detection of preexisting drug-resistant minority variant (DRMV) and/or X4 HIV-1 variants could improve the efficacy of first-line combined antiretroviral therapy (ART) in late presenters. Post-hoc, combined analysis of two open-label, prospective, randomized clinical
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service